

**mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis, Purification, Manufacturing & Scale-up), Application (CGT, Vaccines) - Global Forecast to 2029**

Market Report | 2024-10-16 | 344 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The mRNA synthesis and manufacturing market is expected to reach USD 738.3 million in 2029 from USD 624.4 million in 2024, at a CAGR of 3.4% during the forecast period. mRNA therapeutics hold promise as the next generation of drugs for tissue restoration in regenerative medicine. The development of non-immunogenic mRNA can be achieved through the use of modified nucleosides, which enhances safety and efficacy. By altering the mRNA structure, researchers can create stable, non-immunogenic mRNA through in vitro transcription. Furthermore, effective delivery strategies tailored specifically for mRNA are crucial for the advancement of these therapies. The processes involved in loading and releasing mRNA from biomaterials are essential for their application in tissue restoration and require further refinement to maximize their potential.

"The transcription consumables segment accounted for the largest share by product segment in the mRNA synthesis and manufacturing market in 2023."

Based on product, the mRNA synthesis and manufacturing market is segmented into consumables, and instrument. In 2023, the consumables segment accounted for the largest share of mRNA synthesis and manufacturing market; this segment is further segmented into transcription consumables, purification consumables, and analysis & characterization consumables. Dominance of the consumables segment throughout the forecast period is attributed to the fact that they are essential for mRNA synthesis and manufacturing. Unlike instruments, which are a one-time investment, consumables must be replenished regularly, leading to continuous demand. Also, the entire market operates majorly on instruments offered by Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), whereas more companies operate in the consumables space for mRNA synthesis and manufacturing.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

"The mRNA synthesis & modification service segment is expected to grow at the highest growth rate in the mRNA synthesis and manufacturing market throughout the forecast period."

Based on service, the mRNA synthesis and manufacturing market is segmented into mRNA synthesis & modification, mRNA purification, mRNA analysis & characterization, and manufacturing & scale-up. In 2023, the mRNA synthesis & modification segment accounted for the largest share of the mRNA synthesis and manufacturing market. A significant driver for the mRNA synthesis and modification services within the mRNA synthesis and manufacturing market is the growing need for customized mRNA sequences and modifications to enhance the efficacy and stability of therapeutic and vaccine candidates, which requires specialized synthesis and modification services. As the application of mRNA technology expands, researchers and developers increasingly seek tailored mRNA sequences that can be optimized for specific therapeutic outcomes, such as improved protein expression or enhanced immune response.

"The Asia Pacific region is growing at the highest CAGR in the mRNA synthesis and manufacturing market from 2024 to 2029." The mRNA synthesis and manufacturing market is segmented into six major regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific is the fastest-growing regional segment in the global mRNA synthesis and manufacturing market. Factors such as rising healthcare expenditure; growing R&D expansion in key markets such as India, China, and Japan; low labor costs; and the favorable regulatory environment in the region are expected to contribute to market growth. China's mRNA synthesis and manufacturing market is driven by the country's substantial government investments in biotech innovation, rapid expansion of domestic biotech infrastructure, and increasing international collaborations. In recent developments, China has demonstrated a strong commitment to advancing mRNA technology.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
- By Designation: Directors - 50%, Managers - 30%, and Others - 20%
- By Region: North America -40%, Europe -35%, Asia-Pacific -20%, ROW -5%

List of Companies Profiled in the Report:

- Merck KGaA (Germany)
- Thermo Fisher Scientific Inc. (US)
- GenScript (US)
- New England Biolabs (US)
- AldevronLLC. (Danaher Corporation) (US)
- Promega Corporation (US)
- Sartorius AG (Germany)
- WuXi Biologics (China)
- Takara Bio Inc. (Japan)
- GENEWIZ (Azenta USInc.) (US)
- TriLink BioTechnologies (US)
- Lonza (Switzerland)
- Telesis Bio Inc. (US)
- Aurigene Pharmaceutical Services Ltd. (Dr. Reddy's Laboratories Ltd.) (India)
- ST Pharm (South Korea)AGC Biologics (US)

Research Coverage:

This research report categorizes the mRNA synthesis and manufacturing market by Product (transcription consumables, purification consumables, analysis & characterization consumables, and instrument), Application (cell and gene therapy, vaccine, and other applications), End User (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the mRNA synthesis and manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the mRNA synthesis and manufacturing market. Competitive analysis of top players and upcoming startups in the mRNA synthesis and manufacturing market ecosystem is covered in this report.

#### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall mRNA synthesis and manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (Growing focus on mRNA-based vaccine development, expanding therapeutic applications of mRNA technology, advancements in mRNA synthesis technology, increased outsourcing for mRNA synthesis and modification, and collaborations among industry players), restraints (High production cost, stringent regulations), opportunities (Advancements in drug delivery technologies, increased government funding and private investment, applications in regenerative medicines), and challenges (Stability, storage, and manufacturing scalability) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the mRNA synthesis and manufacturing market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the mRNA synthesis and manufacturing market
- Competitive Assessment: Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), GenScript (US), New England Biolabs (US), Aldevron, LLC. (Danaher Corporation) (US), Promega Corporation (US), Sartorius AG (Germany), WuXi Biologics (China), Takara Bio Inc. (Japan), GENEWIZ (Azena US, Inc.) (US), TriLink BioTechnologies (US), Lonza (Switzerland), Telesis Bio Inc. (US), Aurigene Pharmaceutical Services Ltd. (Dr. Reddy's Laboratories Ltd.) (India), ST Pharm (South Korea), AGC Biologics (US), among others in the market.

#### Table of Contents:

1□INTRODUCTION□	34
1.1□STUDY OBJECTIVES□	34
1.2□MARKET DEFINITION□	34
1.3□STUDY SCOPE□	34
1.3.1□MARKETS COVERED AND REGIONAL SCOPE□	35
1.3.2□INCLUSIONS AND EXCLUSIONS□	36
1.3.3□YEARS CONSIDERED□	36
1.4□CURRENCY CONSIDERED□	36
1.5□STAKEHOLDERS□	37
2□RESEARCH METHODOLOGY□	38
2.1□RESEARCH DATA□	38
2.1.1□SECONDARY DATA□	38
2.1.2□PRIMARY DATA□	39
2.2□MARKET SIZE ESTIMATION□	41
2.2.1□GLOBAL MARKET SIZE ESTIMATION□	42
2.2.2□INSIGHTS FROM PRIMARY SOURCES□	45
2.2.3□TOP-DOWN APPROACH□	45
2.3□GROWTH RATE PROJECTIONS□	46

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.4	DATA TRIANGULATION	48
2.5	RESEARCH ASSUMPTIONS	49
2.6	RESEARCH LIMITATIONS	50
2.7	RISK ANALYSIS	50
3	EXECUTIVE SUMMARY	51
4	PREMIUM INSIGHTS	56
4.1	MRNA SYNTHESIS & MANUFACTURING MARKET OVERVIEW	56
4.2	NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT AND COUNTRY, 2023	57
4.3	MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET: GLOBAL GROWTH OPPORTUNITIES	57
?		
5	MARKET OVERVIEW	58
5.1	INTRODUCTION	58
5.2	MARKET DYNAMICS	58
5.2.1	DRIVERS	59
5.2.1.1	Rise in clinical trials for mRNA vaccines	59
5.2.1.2	Continuous improvements in design, delivery systems, and manufacturing processes	60
5.2.1.3	Increased outsourcing of mRNA synthesis and production	61
5.2.1.4	Advantages of mRNA-based technology over recombinant expression	61
5.2.2	RESTRAINTS	62
5.2.2.1	High production cost	62
5.2.2.2	Stringent regulations	62
5.2.3	OPPORTUNITIES	63
5.2.3.1	Ongoing innovations in nanoparticles and cell-specific delivery technologies	63
5.2.3.2	Expanding applications of mRNA technology	63
5.2.3.3	Increased government funding and private investments	65
5.2.4	CHALLENGES	66
5.2.4.1	Stability, storage, and manufacturing scalability issues	66
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	66
5.4	REGULATORY LANDSCAPE	67
5.4.1	REGULATORY SCENARIO	67
5.4.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	69
5.5	VALUE CHAIN ANALYSIS	71
5.6	TECHNOLOGY ANALYSIS	72
5.6.1	KEY TECHNOLOGIES	72
5.6.1.1	In vitro transcription	72
5.6.1.2	Poly(A) tail synthesis	73
5.6.1.3	RNA stabilization technologies	73
5.6.2	COMPLEMENTARY TECHNOLOGIES	73
5.6.2.1	Next-generation sequencing	73
5.6.2.2	Gene cloning and vector construction	74
5.6.2.3	DNA amplification	74
5.6.3	ADJACENT TECHNOLOGIES	74
5.6.3.1	Spectrophotometry	74
5.6.3.2	Electrophoresis	75
5.6.3.3	High-performance liquid chromatography	75
5.7	PRICING ANALYSIS	75
5.7.1	AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY INSTRUMENT	76

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.7.2	AVERAGE SELLING PRICE TREND FOR CONSUMABLES	76
5.7.3	AVERAGE SELLING PRICE, BY REGION	77
5.8	PATENT ANALYSIS	78
5.9	SUPPLY CHAIN ANALYSIS	79
5.10	ECOSYSTEM ANALYSIS	81
5.11	KEY CONFERENCES AND EVENTS, 2024-2025	83
5.12	PORTER'S FIVE FORCES ANALYSIS	84
5.12.1	INTENSITY OF COMPETITIVE RIVALRY	85
5.12.2	BARGAINING POWER OF SUPPLIERS	85
5.12.3	BARGAINING POWER OF BUYERS	85
5.12.4	THREAT OF SUBSTITUTES	85
5.12.5	THREAT OF NEW ENTRANTS	86
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	86
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	86
5.13.2	KEY BUYING CRITERIA, BY END USER (PRODUCT)	87
5.14	INVESTMENT AND FUNDING SCENARIO	88
5.15	IMPACT OF AI ON MRNA SYNTHESIS & MANUFACTURING MARKET	88
6	MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT	90
6.1	INTRODUCTION	91
6.2	CONSUMABLES	92
6.2.1	TRANSCRIPTION CONSUMABLES	94
6.2.1.1	mRNA synthesis kits	97
6.2.1.1.1	Increasing demand for rapid and efficient mRNA vaccine development to augment growth	97
6.2.1.1.2	mRNA profiling kits	99
6.2.1.1.2.1	Growing need for precision medicine and personalized therapies to propel market	99
6.2.1.3	RNA polymerases	101
6.2.1.3.1	Growing demand for high-quality and scalable mRNA production to boost market	101
6.2.1.4	Plasmid DNA/DNA templates	103
6.2.1.4.1	Rapid growth of mRNA-based therapeutics and vaccines to expedite growth	103
6.2.1.5	Nucleotides	105
6.2.1.5.1	Need to support diverse research & development initiatives to promote growth	105
6.2.1.6	Vectors	107
6.2.1.6.1	Need for reliable and high-capacity vectors to propel market	107
6.2.1.7	Other transcription consumables	109
?		
6.2.2	PURIFICATION CONSUMABLES	111
6.2.2.1	Purification kits & reagents	114
6.2.2.1.1	Rising focus on quality assurance to encourage growth	114
6.2.2.2	Chromatography filters & membranes	116
6.2.2.2.1	Growing emphasis on process optimization and cost-efficiency in large-scale production to drive market	116
6.2.2.3	Other purification consumables	118
6.2.3	ANALYSIS & CHARACTERIZATION CONSUMABLES	120
6.2.3.1	Analysis kits & reagents	122
6.2.3.1.1	Emerging applications of mRNA beyond vaccines to support growth	122
6.2.3.2	Other analysis & characterization consumables	124
6.3	INSTRUMENTS	126
6.3.1	NEED TO REDUCE PRODUCTION COST AND HIGHER SCALABILITY TO PROMOTE GROWTH	126

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7	MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION	129
7.1	INTRODUCTION	130
7.2	CELL & GENE THERAPIES	130
7.2.1	RIISING ADOPTION OF MRNA TECHNOLOGY TO TREAT GENETIC DISORDERS AND CANCER TO FUEL MARKET	130
7.3	VACCINES	132
7.3.1	INCREASING DEVELOPMENT AND DEPLOYMENT OF MRNA VACCINES TO ACCELERATE GROWTH	132
7.4	OTHER APPLICATIONS	134
8	MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER	137
8.1	INTRODUCTION	138
8.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	138
8.2.1	NEED TO RESPOND TO EMERGING INFECTIOUS DISEASES TO DRIVE MARKET	138
8.3	ACADEMIC & RESEARCH INSTITUTIONS	141
8.3.1	INCREASING INVESTMENTS IN RESEARCH TO EXPEDITE GROWTH	141
8.4	CROS & CDMOS	143
8.4.1	RIISING DEMAND FOR OUTSOURCED SERVICES TO AID GROWTH	143
9	MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE	146
9.1	INTRODUCTION	147
9.2	MRNA SYNTHESIS & MODIFICATION SERVICES	147
9.2.1	GROWING NEED FOR CUSTOMIZED MRNA SEQUENCES AND MODIFICATIONS TO FUEL MARKET	147
9.3	MRNA PURIFICATION SERVICES	149
9.3.1	NEED FOR PERSONALIZED MRNA VACCINES TO BOOST MARKET	149
9.4	MRNA ANALYSIS & CHARACTERIZATION SERVICES	151
9.4.1	INCREASING REGULATORY SCRUTINY TO EXPEDITE GROWTH	151
9.5	MANUFACTURING & SCALE-UP SERVICES	153
9.5.1	GROWING TRANSITION FROM SMALL-SCALE RESEARCH & DEVELOPMENT TO LARGE-SCALE COMMERCIAL PRODUCTION TO DRIVE MARKET	153
10	MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER	156
10.1	INTRODUCTION	157
10.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	157
10.2.1	RAPID DEVELOPMENT AND COMMERCIALIZATION OF MRNA-BASED PRODUCTS TO ENCOURAGE GROWTH	157
10.3	ACADEMIC & RESEARCH INSTITUTIONS	160
10.3.1	INCREASING EMPHASIS ON TRANSLATING MRNA-BASED DISCOVERIES INTO PRACTICAL APPLICATIONS TO AID GROWTH	160
10.4	SMALL-SCALE CROS & CDMOS	162
10.4.1	NEED FOR SPECIALIZED AND FLEXIBLE PRODUCTION IN BIOTECH COMPANIES AND EARLY-STAGE MRNA PROJECTS TO BOOST MARKET	162
11	MRNA SYNTHESIS & MANUFACTURING MARKET, BY REGION	165
11.1	INTRODUCTION	166
11.2	NORTH AMERICA	167
11.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	171
11.2.2	US	172
11.2.2.1	Increasing demand for mRNA-based vaccines and therapeutics to accelerate growth	172
11.2.3	CANADA	176
11.2.3.1	Increasing collaborations between academic institutions and market players to spur growth	176
11.3	EUROPE	179
11.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	183
11.3.2	GERMANY	184
11.3.2.1	Growing establishment of manufacturing sites to boost market	184

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

11.3.3	UK	188
11.3.3.1	Presence of state-of-the-art facilities to support growth	188
11.3.4	FRANCE	191
11.3.4.1	Favorable government support for biopharmaceutical production to drive market	191
11.3.5	SWITZERLAND	195
11.3.5.1	Robust biotech sector and production facilities to promote growth	195
11.3.6	ITALY	198
11.3.6.1	Increasing collaborations among biotech firms and manufacturing facilities to aid growth	198
11.3.7	SPAIN	202
11.3.7.1	Growing investments in biotechnology to fuel market	202
11.3.8	REST OF EUROPE	205
?		
11.4	ASIA PACIFIC	209
11.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	214
11.4.2	CHINA	214
11.4.2.1	Rapid expansion of domestic biotech sector to contribute to growth	214
11.4.3	JAPAN	218
11.4.3.1	Growing strategic investments in biotechnology infrastructure to boost market	218
11.4.4	INDIA	221
11.4.4.1	Booming biotech sector and international collaborations to augment growth	221
11.4.5	SOUTH KOREA	225
11.4.5.1	Increased government funding in research and vaccine development to bolster growth	225
11.4.6	REST OF ASIA PACIFIC	228
11.5	LATIN AMERICA	232
11.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	236
11.5.2	BRAZIL	237
11.5.2.1	Increased funding for strengthening infrastructure to sustain growth	237
11.5.3	REST OF LATIN AMERICA	240
11.6	MIDDLE EAST	243
11.6.1	GROWING INVESTMENTS FROM PRIVATE SECTOR AND ACADEMIC RESEARCH INITIATIVES TO DRIVE MARKET	243
11.6.2	MACROECONOMIC OUTLOOK IN MIDDLE EAST	247
11.7	AFRICA	248
11.7.1	GROWING INITIATIVES TO ENHANCE LOCAL PRODUCTION CAPABILITIES TO PROPEL MARKET	248
11.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	251
12	COMPETITIVE LANDSCAPE	252
12.1	INTRODUCTION	252
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021-AUGUST 2024	252
12.3	REVENUE ANALYSIS, 2019-2023	254
12.4	MARKET SHARE ANALYSIS, 2023	255
12.4.1	MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET	255
12.4.2	MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET	256
12.5	COMPANY VALUATION AND FINANCIAL METRICS	257
12.6	BRAND/SERVICE COMPARISON	259
12.6.1	ALDEVRON LLC (DANAHER CORPORATION) (US)	259
12.6.2	THERMO FISHER SCIENTIFIC INC. (US)	260
12.6.3	TRILINK BIOTECHNOLOGIES (US)	260
12.6.4	LONZA (SWITZERLAND)	260

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

12.6.5	MERCK KGAA (GERMANY)	260
?		
12.7	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	260
12.7.1	STARS	261
12.7.2	EMERGING LEADERS	261
12.7.3	PERVASIVE PLAYERS	261
12.7.4	PARTICIPANTS	261
12.7.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	263
12.7.5.1	Company footprint	263
12.7.5.2	Region footprint	263
12.7.5.3	Product footprint	264
12.7.5.4	Service footprint	265
12.7.5.5	Application footprint	266
12.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	267
12.8.1	PROGRESSIVE COMPANIES	267
12.8.2	RESPONSIVE COMPANIES	267
12.8.3	DYNAMIC COMPANIES	267
12.8.4	STARTING BLOCKS	267
12.8.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	268
12.8.5.1	Detailed list of key startups/SMEs	268
12.8.5.2	Competitive benchmarking of key startups/SMES	269
12.9	COMPETITIVE SCENARIO	270
12.9.1	PRODUCT/SERVICE LAUNCHES	270
12.9.2	DEALS	271
12.9.3	EXPANSIONS	271
13	COMPANY PROFILES	273
13.1	KEY PLAYERS	273
13.1.1	THERMO FISHER SCIENTIFIC INC.	273
13.1.1.1	Business overview	273
13.1.1.2	Products/Services offered	274
13.1.1.3	Recent developments	276
13.1.1.3.1	Product/Service launches	276
13.1.1.3.2	Deals	276
13.1.1.3.3	Expansions	276
13.1.1.4	MnM view	277
13.1.1.4.1	Key strengths	277
13.1.1.4.2	Strategic choices	277
13.1.1.4.3	Weaknesses and competitive threats	277
?		
13.1.2	DANAHER CORPORATION	278
13.1.2.1	Business overview	278
13.1.2.2	Products/Services offered	279
13.1.2.3	Recent developments	281
13.1.2.3.1	Product/Service launches	281
13.1.2.3.2	Deals	281
13.1.2.3.3	Expansions	281
13.1.2.4	MnM view	282

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



13.1.2.4.1	Key strengths	282
13.1.2.4.2	Strategic choices	282
13.1.2.4.3	Weaknesses and competitive threats	282
13.1.3	MERCK KGAA	283
13.1.3.1	Business overview	283
13.1.3.2	Products/Services offered	284
13.1.3.3	Recent developments	287
13.1.3.3.1	Deals	287
13.1.3.3.2	Expansions	287
13.1.3.4	MnM view	288
13.1.3.4.1	Key strengths	288
13.1.3.4.2	Strategic choices	288
13.1.3.4.3	Weaknesses and competitive threats	288
13.1.4	LONZA	289
13.1.4.1	Business overview	289
13.1.4.2	Products/Services offered	290
13.1.4.3	Recent developments	291
13.1.4.3.1	Deals	291
13.1.4.3.2	Expansions	291
13.1.4.4	MnM view	292
13.1.4.4.1	Key strengths	292
13.1.4.4.2	Strategic choices	292
13.1.4.4.3	Weaknesses and competitive threats	292
13.1.5	MARVAI LIFESCIENCES	293
13.1.5.1	Business overview	293
13.1.5.2	Products/Services offered	294
13.1.5.3	Recent developments	297
13.1.5.3.1	Product/Service launches	297
13.1.5.3.2	Deals	297
13.1.5.3.3	Expansions	298
13.1.5.4	MnM view	298
13.1.5.4.1	Key strengths	298
13.1.5.4.2	Strategic choices	298
13.1.5.4.3	Weaknesses and competitive threats	298
13.1.6	NEW ENGLAND BIOLABS	299
13.1.6.1	Business overview	299
13.1.6.2	Products/Services offered	299
13.1.6.3	Recent developments	300
13.1.6.3.1	Product/Service launches	300
13.1.7	PROMEGA CORPORATION	301
13.1.7.1	Business overview	301
13.1.7.2	Products/Services offered	301
13.1.7.3	Recent developments	302
13.1.7.3.1	Expansions	302
13.1.7.3.2	Other developments	302
13.1.8	GENSCRIPT	303
13.1.8.1	Business overview	303

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.1.8.2□Products/Services offered□304
- 13.1.8.3□Recent developments□305
- 13.1.8.3.1□Product/Service launches□305
- 13.1.8.3.2□Deals□306
- 13.1.8.3.3□Expansions□306
- 13.1.8.4□MnM view□307
- 13.1.8.4.1□Key strengths□307
- 13.1.8.4.2□Strategic choices□307
- 13.1.8.4.3□Weaknesses and competitive threats□307
- 13.1.9□WUXI BIOLOGICS□308
- 13.1.9.1□Business overview□308
- 13.1.9.2□Products/Services offered□309
- 13.1.9.3□Recent developments□310
- 13.1.9.3.1□Expansions□310
- 13.1.10□TAKARA BIO INC.□311
- 13.1.10.1□Business overview□311
- 13.1.10.2□Products/Services offered□312
- 13.1.10.3□Recent developments□313
- 13.1.10.3.1□Product/Service launches□313
- 13.1.10.3.2□Deals□313
- 13.1.11□SARTORIUS AG□314
- 13.1.11.1□Business overview□314
- 13.1.11.2□Products/Services offered□315
- 13.1.11.3□Recent developments□316
- 13.1.11.3.1□Deals□316
- 13.1.12□GENEWIZ□317
- 13.1.12.1□Business overview□317
- 13.1.12.2□Products/Services offered□318
- ?
- 13.1.13□TELESIS BIO INC.□319
- 13.1.13.1□Business overview□319
- 13.1.13.2□Products/Services offered□320
- 13.1.13.3□Recent developments□321
- 13.1.13.3.1□Product/Service launches□321
- 13.1.13.3.2□Deals□321
- 13.1.14□ST PHARM□322
- 13.1.14.1□Business overview□322
- 13.1.14.2□Products/Services offered□323
- 13.1.14.3□Recent developments□323
- 13.1.14.3.1□Deals□323
- 13.1.15□AGC BIOLOGICS□324
- 13.1.15.1□Business overview□324
- 13.1.15.2□Products/Services offered□324
- 13.1.15.3□Recent developments□325
- 13.1.15.3.1□Deals□325
- 13.1.15.3.2□Expansions□325
- 13.1.16□DR. REDDY'S LABORATORIES LTD.□326

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.16.1	Business overview	326
13.1.16.2	Products/Services offered	327
13.1.16.3	Recent developments	327
13.1.16.3.1	Expansions	327
13.2	OTHER PLAYERS	328
13.2.1	ETHERNA	328
13.2.2	BOC SCIENCES	329
13.2.3	BIOMAY AG	330
13.2.4	CURIA GLOBAL, INC.	331
13.2.5	JENA BIOSCIENCE GMBH	332
13.2.6	ENZYNOMICS CO., LTD.	333
13.2.7	KANEKA EUROGENTEC S.A.	334
13.2.8	VERNAL BIOSCIENCES	334
13.2.9	CELLSCRIPT	335
14	APPENDIX	336
14.1	DISCUSSION GUIDE	336
14.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	340
14.3	CUSTOMIZATION OPTIONS	342
14.4	RELATED REPORTS	342
14.5	AUTHOR DETAILS	343

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis, Purification, Manufacturing & Scale-up), Application (CGT, Vaccines) - Global Forecast to 2029**

Market Report | 2024-10-16 | 344 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

Signature